Latest News

Sales of Julphar Grow by 19 per cent in 1st quarter of 2014

 Gulf Pharmaceutical Industries ''Julphar''

Gulf Pharmaceutical Industries ”Julphar”

Julphar (Gulf Pharmaceutical Industries) registered sales revenue of AED 393.5 million in the first quarter of the year 2014, up 19.2% year-on-year (yoy). Sales during the quarter, ended March 31, were driven by private market sales which saw a yoy growth of 14.3%.

The company continued to show strong operational performance during the period. Gross Profit during the quarter was AED 237.1 million, up 18.3% yoy. Profit for the quarter was AED 70.1 million, up 12.0% yoy.

In a step that reflected the company’s strong performance in 2013, the general assembly of Julphar held last month decided to distribute to shareholders 10% of profits in cash in addition to another 10% in shares from a total capital amount of AED863.151m.

Also, supporting the UAE leading Emiratisation initiative “Absher”, Julphar has recently decided to allocate half million bonds, out of a total of 50 million bonds issued to raise the company’s capital, for the benefit of the company’s Emirati employees.

Established in 1980, Julphar is a regional leader in the production and distribution of high quality, affordable pharmaceutical products, having a manufacturing network consists of twelve world-class production facilities and a reliable logistics network which spans five continents.

Their diverse product portfolio contains over 800 products and targets major therapeutic segments including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management.

Source : WAM News Agency for United Arab Emirates


Read more opinions >